, a polyphenolic compound found in juice and wine from dark-skinned grape cultivars, was recently shown to bind to estrogen receptors in vitro, where it activated transcription of estrogen-responsive reporter genes. The purpose of this 6-day study in weanling rats was to determine the dose response (1, 4, 10, 40, and 100 g/day) effects of orally administered resveratrol on estrogen target tissues. The solvent (10% ethanol) had no significant effect on any measurement or derived value. 17␤-Estradiol treatment (100 g/day) decreased the growth rate, final body weight, serum cholesterol, and radial bone growth (periosteal bone formation and mineral apposition rates) at the tibia-fibula synostosis. In the uterus, 17␤-estradiol treatment increased wet weight, epithelial cell height, and steady state messenger RNA levels for insulin-like growth factor I. In contrast, resveratrol treatment had no significant effect on body weight, serum cholesterol, radial bone growth, epithelial cell height, or messenger RNA levels for insulinlike growth factor I. Resveratrol treatment resulted in slight increases in uterine wet weight, but significance was achieved at the 10-g dose only. A second experiment was performed to determine whether a high dose of resveratrol (1000 g/day) antagonizes the ability of estrogen to lower serum cholesterol. As was shown for the lower doses, resveratrol had no effect on body weight, uterine wet weight, uterine epithelial cell height, cortical bone histomorphometry, or serum cholesterol. 17␤-Estradiol significantly lowered serum cholesterol, and this response was antagonized by cotreatment with resveratrol. These in vivo results suggest, in contrast to prior in vitro studies, that resveratrol has little or no estrogen agonism on reproductive and nonreproductive estrogen target tissues and may be an estrogen antagonist. (Endocrinology 140: 50 -54, 1999) 
T RANS-RESVERATROL (resveratrol) is a polyphenolic
compound that is found in fresh grapes, grape juice, and wine. Resveratrol is localized in the grape skin; its concentration varies with specific grape cultivar, climate, and viticultural practices (1) (2) (3) . Higher concentrations of resveratrol are found in dark-skinned grapes than in light-skinned varieties (2) . As a consequence of the differences between the varieties and methods of processing the grapes, red wines usually contain more resveratrol than white, rosé, or blush wines (2) .
Resveratrol has been implicated in many (4 -7), but not all (8, 9) , studies as a mediator of the alcohol-independent cardiovascular protection that is allegedly conferred by drinking red wine. Recently, resveratrol was shown to compete with 17␤-estradiol for estrogen receptors in vitro (10) . Additionally, resveratrol activated transcription of estrogen-responsive reporter genes transfected into human breast cancer cells (10) . The physiological significance of these findings are unknown because resveratrol has not yet been shown to have effects on estrogen target tissues in vivo. With this in mind, we now report the dose-response effects of resveratrol on representative reproductive and nonreproductive estrogen target tissues in weanling rats.
Materials and Methods Animals
These studies were approved by the Mayo Foundation institutional animal care and use committee.
Exp 1
This study was performed to determine whether resveratrol is an estrogen agonist on selected reproductive and nonreproductive estrogen target tissues. Forty-two weanling (3-week-old) female Sprague-Dawley rats were obtained from Harlan Sprague-Dawley, Inc. (Indianapolis, IN). The rats were weighed and randomly divided into eight groups, with five or six animals per group. The groups consisted of 1) untreated, 2) solvent treated, 3) estrogen treated (100 g/day), and 4 -8) resveratrol treated (1, 4, 10, 40 , and 100 g/day, respectively). Resveratrol (Sigma Chemical Co., St. Louis, MO) was dissolved in 95% ethanol and diluted with water. Part (0.5 ml) of the final 10% ethanol solution was administered to the rats once a day orally by gavage. 17␤-Estradiol was administered to the rats ip. For bone histomorphometry, the fluorochrome calcein (20 mg/kg; Sigma Chemical Co.) was administered by tail vein injection at the start of the experiment and 1 day before death. The rats were weighed and anesthetized with ketamine HCl (16.4 mg)-xylazine HCl (0.18 mg), and trunk blood was collected after decapitation.
After death, the uterus was quickly excised, freed of connective tissue, weighed, and frozen in liquid N 2 . The uteri were stored frozen at Ϫ84 C until RNA was isolated. The tibiae were excised and stored in 70% ethanol until they were processed for bone histomorphometry.
Exp 2
This study was performed to determine whether resveratrol antagonizes the ability of estrogen to lower serum cholesterol. Forty-two weanling Sprague-Dawley rats were obtained from Harlan SpragueDawley, Inc. The rats were weighed and randomly divided into eight groups, with five (treatment groups) or seven (solvent-treated control group) animals per group. The groups consisted of 1) solvent treated control, 2-4) 17␤-estradiol treated (1, 10, and 100 g/day, respectively), 5) resveratrol treated (1000 g/day), and 6 -8) combination treatment with resveratrol (1000 g/day) and 17␤-estradiol (1, 10, and 100 g/day, respectively). The treatments were given daily by gavage as described in Exp 1. After 6 days of treatment the rats were killed and necropsied as described in Exp 1.
Mean growth rate
The mean growth rate was calculated as the difference between final weight and starting weight divided by 6 days.
Serum cholesterol
Serum cholesterol was determined by the Immunochemical Laboratory Core Facility at the Mayo Clinic using an automated procedure (Roche Diagnostic System, Los Angeles, CA). Cholesterol is released from its esters by the enzymatic action of an ester hydroxylase. Free cholesterol is then oxidized by cholesterol oxidase, producing hydrogen peroxide. The hydrogen peroxide, when combined with 4-amino-antipyrine and phenol, forms a chromophore in an amount that is directly proportional to the cholesterol concentration and is quantitated photometrically.
Histomorphometry
All measurements were performed with an Osteomeasure semiautomatic image analysis system (Osteomeasure, Atlanta, GA), which has been described in detail previously (11) .
All cortical measurements were made on 20-m-thick unstained, undemineralized ground sections as previously described (11) . The primary static measurements consisted of cross-sectional area and medullary area. Cortical area was calculated as previously described (11) . The primary dynamic measurements consisted of bone formed during the interval between administration of the sequential fluorochrome labels and labeled perimeter. The bone formation and mineral apposition rates were calculated from these data as previously described (11) .
Uterine histology
Epithelial cell height was measured in 7-m-thick microtome-cut sections of paraffin-embedded uterine tissue as previously described (12) .
RNA analyses
Total cellular RNA was isolated from uteri as previously described (13) . A ribonuclease (RNase) protection assay was used to measure steady state levels messenger RNA (mRNA) levels for insulin-like growth factor I (IGF-I) and L32. IGF-I is an important growth factor that is rapidly up-regulated by estrogen in the uterus. L32 is a ribosomal protein. The mRNA levels for IGF-I were normalized to L32 to correct for differences in the amounts of RNA that were hybridized with the probes. The assay was performed using the kit as recommended by the manufacturer (Ambion, Inc., Austin, TX). Antisense IGF-I RNA probe was synthesized using T3 RNA polymerase and a cloned fragment of IGF-I complementary DNA as previously described (14) . L32 antisense RNA probe was synthesized using T7 RNA polymerase and complementary DNA fragment purchased from PharMingen (San Diego, CA). The purified antisense RNA probes of IGF-I and L-32 (3 ϫ 10 6 cpm each) were hybridized with 20 g total cellular RNA isolated from tissues for 18 h at 43 C as described by the manufacturer (Ambion, Inc.). The RNase-digested, protected fragments were separated on acrylamideurea gels. Quantitation of protected IGF-I and L32 RNA fragments was performed by PhosphorImage analyses (Molecular Dynamics, Inc., Sunnyvale, CA). The sizes of the protected IGF-I and L32 mRNA fragments are 226 and 112 bp, respectively.
Statistical analysis
Measurements in which statistical significance was P Ͻ 0.05 by oneway ANOVA were tested by multiple comparisons using the Fisher protected least significant difference post-hoc test to establish group differences.
Results

General
The animals appeared healthy. The solvent (10% ethanol) had no effect on any measured or calculated value compared with that in untreated rats (data not shown).
Exp 1
Body weight. The weight data are shown in Table 1 . All treatment groups grew during the 6-day experiment. Resveratrol had no effect on either final body weight or mean growth rate, with the exception of a small decrease in the calculated mean growth rate at the highest dose rate. These largely negative findings contrast with the pronounced inhibitory effect of estrogen treatment on the final body weight and mean growth rate.
Uterus. Uterine wet weight, epithelial cell height, and the steady state IGF-I mRNA level were measured (Fig. 1) to evaluate the dose-dependent effects of resveratrol on selected indexes of uterine growth and differentiation. A phosphoimage of a representative RNase protection assay for IGF-I is shown in Fig. 2 . As expected, high levels of the mRNA for IGF-I were expressed in the uterus. None of the treatments had any effect on mRNA levels for ribosomal protein L32. 17␤-Estradiol increased uterine weight (Fig. 1A) , epithelial cell height (Fig. 1B) , and mRNA levels for IGF-I (Fig. 1C ) compared with those in the solvent-treated controls. Resveratrol treatment resulted in a tendency toward slight increases in uterine wet weight, epithelial cell height, and mRNA levels for IGF-I. No dose response was observed, and with the exception of increased uterine weight at one dose (10 g), statistical significance was not achieved. Fig. 3 . 17␤-Estradiol decreased serum cholesterol compared with that in age-matched controls, whereas resveratrol had no effect on serum cholesterol.
Serum cholesterol. Serum cholesterol is shown in
Cortical bone measurements. The static and dynamic cortical bone measurements are tabulated in Table 2 . None of the treatments altered cross-sectional area, medullary area or cortical bone area. 17␤-Estradiol decreased the periosteal bone formation and mineralization rates compared with the controls. On the other hand, resveratrol had no effect on dynamic cortical bone measurements.
Exp 2
Resveratrol (1000 g/day) had no significant effect on body weight, weight gain, uterine wet weight, uterine epithelial cell height, or cortical bone histomorphometry (data not shown). The effects of resveratrol, 17␤-estradiol, and combination treatment on serum cholesterol are shown in Fig. 4 . Resveratrol treatment had no effect on serum choles- terol. Resveratrol antagonized the cholesterol-lowering activity of the two lower doses of 17␤-estradiol, but did not prevent the cholesterol-lowering activity of the highest dose.
Discussion
Our in vivo results demonstrate that resveratrol does not stimulate indexes of uterine growth and differentiation in immature rats; even very high doses of resveratrol generally had insignificant effects on uterine wet weight, epithelial cell height, and IGF-I gene expression. Additionally, resveratrol had no effect on other estrogen target tissues; treatment with resveratrol did not alter cortical bone growth, the serum concentration of cholesterol, or body weight. We conclude from these findings that resveratrol is not an estrogen agonist in the rat.
Resveratrol was shown by Gehm et al. (10) to bind to estrogen receptors and activate estrogen-responsive genes in vitro. It was suggested by these authors that the estrogenic actions of resveratrol may be relevant to the reported cardiovascular benefits of drinking wine (10) . However, the weak IC 50 for resveratrol binding to the estrogen receptor of approximately 10 m and the weak EC 50 for estrogenic stimulation of between 3 and 10 m, depending on the test system examined, raise questions regarding the physiological significance of these in vitro findings.
The concentration of resveratrol in grapes, grape juice, and wine is highly variable. Also, grapes contain cis-as well as trans-resveratrol. Although the affinity of cis-resveratrol to the estrogen receptor has not been measured, it's conformation leads one to suspect that the binding will be much weaker than the trans-isomer. The conversion of resveratrol to the cis-isomer is potentiated by heat and UV light and would probably reduce the potential estrogenic activity of this putative phytoestrogen (15, 16) . Additionally, it is possible that resveratrol is metabolized to other products that differ from the parent compound in estrogenic activity. Importantly, only the lowest two dose rates used in the present study for administration of resveratrol fall within the range that a moderate wine drinker might ingest (1) (2) (3) . This contrasts with the higher dose rates studied, which would greatly exceed dietary exposure to resveratrol.
Although we did not measure plasma or tissue levels of resveratrol, such measurements have been measured by Bertelli et al. (15, 16) . Oral administration of 28 g resveratrol in red wine to male rats resulted in peak plasma levels of resveratrol of greater than 20 ng/ml after 1 h. Importantly, resveratrol was shown to be bioavailable to several tissues, including heart, liver, and kidney, and was retained in these tissues.
Resveratrol is sparingly soluble in water. We administered resveratrol in a 10% ethanol solution to model wine. The daily intake of ethanol in this study ranged from 0.75-1.5 g/kg, which is equivalent to a 50-kg human consuming 3-6 glasses of wine. This quantity of ethanol is generally considered to exceed moderation (17) . However, this volume of ethanol is often consumed by nonalcoholics, was essential to solubilize the highest dose rates of resveratrol, and had no significant effect on any measurement performed in this study.
The effects of 17␤-estradiol observed in this study were consistent with previous studies. As expected, the hormone stimulated indexes of uterine growth (wet weight) and differentiation (increased epithelial cell height and steady state IGF-I mRNA levels) and suppressed weight gain, serum cholesterol, and radial bone growth (18 -20) .
Resveratrol had minimal effects on uterine growth and differentiation. Although it is possible that higher concentrations of resveratrol might have more pronounced effects on the uterus, higher doses would not be relevant to the levels present in either grape juice or wine. Furthermore, the competition studies in which resveratrol antagonized the hypocholesterolemic response to estrogen suggest that resveratrol binding to estrogen receptors was achieved. This conclusion has been verified by studies in which we have shown that pretreatment with resveratrol (1000 g) reduces by about 50% the accumulation of tracer levels of [ 3 H]17␤-estradiol into nuclei of uteri from ovariectomized sexually mature rats (Sibonga, J., and R. T. Turner, unpublished results).
Resveratrol had variable effects on activation of estrogenregulated genes in vitro; some were activated to a greater extent than with 17␤-estradiol, whereas others were activated to a lesser extent (10) . These findings suggested that resveratrol might have tissue-selective actions analogous to triphenylethylene-and benzothiophene-selective estrogen receptor modulators (21) . This possibility was not substantiated in the present studies. In contrast to the selective estrogen receptor modulators, resveratrol did not reduce serum concentrations of cholesterol, suppress weight gain, or antagonize radial bone growth.
Estrogen is believed to benefit the cardiovascular system in part by decreasing platelet aggregation and increasing serum low density lipoprotein cholesterol. The ED 50 values for cholesterol lowering by partial estrogen agonists are highly correlated with binding affinity to the estrogen receptor (22) . Furthermore, the potent estrogen antagonist ICI 182,780 increases total serum cholesterol (23) . These findings provide strong support that the hypocholesterolemic activity of estrogen is through an estrogen receptor-mediated mechanism. The effects of resveratrol on platelet aggregation and cholesterol metabolism are controversial (4 -9). In the current studies in weanling rats, neither ethanol nor resveratrol altered total serum cholesterol. However, as 17␤-estradiol reduced total serum cholesterol (19, 23, 24) and resveratrol antagonized that activity, we can conclude that resveratrol is an estrogen antagonist on cholesterol metabolism. Estrogen secretion at puberty is an important determinant of peak bone mass in rats (25) . The inhibition of cortical bone growth in rats by estrogen is well established (18) . Estrogen receptor mRNA has been identified in the periosteum (15) , and the cascade induced by the hormone in this tissue (25) is antagonized by ICI 182,780 (23) . The failure to detect an effect on bone histomorphometry implies that resveratrol is not an estrogen agonist on cortical bone.
We are uncertain whether there are species differences in either the absorption of resveratrol or the binding of resveratrol to estrogen receptors. However, resveratrol has been shown to be absorbed by rats (15, 16) and humans (8) after oral administration of red wine. Furthermore, we are not aware of any major differences between rats and humans in the relative binding of estrogen agonists to estrogen receptors.
Estrogen reduces weight gain in rats in part by decreasing food consumption. Pair feeding ovary-intact and ovariectomized rats is only partially effective in controlling the accumulation of adipose tissue, indicating that gonadal hormones also influence the utilization of calories (18) . The lack of an effect on body weight suggests that resveratrol is not an estrogen agonist on this activity.
In summary, dose-response studies revealed that orally administered resveratrol had minimal in vivo effects on estrogen target tissues in rats, including no effect on uterine growth and differentiation, body weight, serum cholesterol, or radial bone growth. In contrast, resveratrol antagonized the effects of estrogen to lower serum cholesterol. We conclude that it is unlikely that the cardiovascular protective effects of moderate wine drinking are due to the binding and activation of estrogen receptors by resveratrol.
